Pretreatment predictors of short-term nonadherence to oral hormonal therapy for women with breast cancer

Nursing Research

Volumn 62, Issue 4, 2013, Pages 243-251

  Wickersham, Karen E ^a   Sereika, Susan M ^b   Bender, Catherine M ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF NURSING   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

aromatase inhibitors; breast neoplasms; medication nonadherence; tamoxifen

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADJUVANT CHEMOTHERAPY; ALGORITHM; ARTICLE; BREAST TUMOR; COHORT ANALYSIS; FEMALE; HUMAN; LONGITUDINAL STUDY; MEDICATION COMPLIANCE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ORAL DRUG ADMINISTRATION; STATISTICAL MODEL; STATISTICS;

ADMINISTRATION, ORAL; ALGORITHMS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; FEMALE; HUMANS; LINEAR MODELS; LONGITUDINAL STUDIES; MEDICATION ADHERENCE; MIDDLE AGED; MODELS, STATISTICAL; MULTIVARIATE ANALYSIS;

EID: 84879908772     PISSN: 00296562     EISSN: 15389847     Source Type: Journal    
DOI: 10.1097/NNR.0b013e318298fd70     Document Type: Article

References (36)

1. Alfano, C.M., McGregor, B. A., Kuniyuki, A., Reeve, B. B., Bowen, D. J., Baumgartner, K. B.,IMcTiernan, A. (2006). Psychometric properties of a tool for measuring hormone-related symptoms in breast cancer survivors. Psycho-Oncology, 15, 985-1000. (Pubitemid 44762704)
2. AmericanCancer Society. (2012). Oral chemotherapy:What you need toknow. Retrieved from http://www.cancer.org/treatment/treatment sandsideeffects/ treatmenttypes/chemotherapy/oral-chemotherapy
3. Barron, T. I., Connolly, R., Bennett, K., Feely, J., & Kennedy,M. J. (2007). Early discontinuation of tamoxifen: A lesson for oncologists. Cancer, 109, 832-839. (Pubitemid 46333524)
4. Baum,M., Budzar, A. U., Cuzick, J., Forbes, J., Houghton, J. H.,I Sahmoud, T.; ATAC Trialists' Group. (2002). Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet, 359, 2131-2139. (Pubitemid 34694019)
5. Beck, A. T., Steer, R. A.,&Brown, G. K. (1996). Beck Depressive Symptoms Inventory-II. San Antonio, TX: Psychological Corporation.
6. Cassileth, B. R., Soloway, M. S., Vogelzang, N. J., Chou, J. M., Schellhammer, P. D., Seidmon, E. J., & Kennealey, G. T. (1992). Quality of life and psychosocial status in stage D prostate cancer: Zoladex Prostate Cancer Study Group. Quality of Life Research, 1, 323-329.
7. Cella, D., Land, S. R., Chang, C-H., Day, R., Constantino, J. P., Wolmark, N., & Ganz, P. A. (2007). Symptom measurement in the Breast Cancer Prevention Trial (BCPT) (P-1): Psychometric properties of a new measure of symptoms for midlife women. Breast Cancer Research and Treatment, 109, 515-526. (Pubitemid 351692068)
8. Christensen, A. J. (2000). Patient-by-treatment context interaction in chronic disease: A conceptual framework for the study of patient adherence. Psychosomatic Medicine, 62, 435-443. (Pubitemid 30347087)
9. Cohen J. (1988). Statistical power analysis for the behavioral sciences (2nd ed.). Hillsdale, NJ: Erlbaum. Cohen, M. (2002). First degree relatives of breast cancer patients: Cognitive perceptions, coping, and adherence to breast selfexamination. Behavioral Medicine, 28, 15-22.
10. Coombes, R. C., Hall, E., Gibson, L. J., Paridaens, R., Jassem, J., Delozier, T., I van de Velde, C.; Intergroup Exemestane Study. (2004). A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. New England Journal of Medicine, 350, 1081Y1092. (Pubitemid 38298988)
11. Cramer, J. A., Roy, A., Burrell, A., Fairchild, C. J., Fuldeore, M. J., Ollendorf, D. A., & Wong, P. K. (2008). Medication compliance and persistence: Terminology and definitions. Value Health, 11, 44-47. (Pubitemid 351160875)
12. Cramer, J. A., Scheyer, R.D.,&Mattson, R. H. (1990). Compliance declines between clinic visits. Archives of Internal Medicine, 150, 1509-1510. (Pubitemid 20215692)
13. Demissie, S., Silliman, R. A., & Lash, T. L. (2001). Adjuvant tamoxifen: Predictors of use, side effects and discontinuation in older women. Journal of Clinical Oncology, 19, 322-328. (Pubitemid 32112842)
14. Fink, A. K., Gurwitz, J., Rakowski, W., Guadagnoli, E.,& Silliman, R. A. (2004). Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor-positive breast cancer. Journal of Clinical Oncology, 22, 3309-3315. (Pubitemid 41103687)
15. Ganz, P., Greendale, G. A., Petersen, L., Zibecchi, L., Kahn, B., & Belin, T. R. (2000). Managing menopausal symptoms in beast cancer survivors: Results of a randomized controlled trial. Journal of the National Cancer Institute, 92, 1054-1064. (Pubitemid 30618024)
16. Goss, P. E., Ingle, J. N., Martino, S., Robert, N. J., Muss, H. B., Piccart, M. J., I Pater, J. L. (2003). A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. New England Journal of Medicine, 349, 1793-1802. (Pubitemid 37362955)
17. Grunfeld, E. A., Hunter, M. S., Sikka, P., & Mittal, S. (2005). Adherence beliefs among breast cancer patients taking tamoxifen. Patient Education and Counseling, 59, 97-102. (Pubitemid 41399883)
18. Haynes, R. B., Ackloo, E., Sahota, N., McDonald, H., & Yao, X. (2008). Interventions for enhancing medication adherence. The Cochrane Collaboration, 2, CD000011.
19. Jonat, W., Pritchard, K. I., Sainsbury, R., & Klijn, J. G. (2006). Trends in endocrine therapy and chemotherapy for early breast cancer: A focus on the premenopausal patient. Journal of Cancer Research and Clinical Oncology, 132, 275-286.
20. Kahn, K. L., Schneider, E. C., Malin, J. L., Adams, J. L., & Epstein, A. M. (2007). Patient centered experiences in breast cancer: Predicting long-term adherence to tamoxifen use. Medical Care, 45, 431-439.
21. Lash, T.L,&Fox,M. P.,Westrup, J. L., Fink, A.K.,&Silliman,R.A. (2006). Adherence to tamoxifen over the five-year course. Breast Cancer Research and Treatment 99. 215-220 (Pubitemid 44268270)
22. Lebovits,A.H., Strain, J. J., Schleifer, S. J.,Tanaka, J. S.,Bhardwaj, S., & Messe, M. R. (1990). Patient noncompliance with selfadministered chemotherapy. Cancer, 65, 17-22.
23. Mason, B. J.,Matsuyama, J. R., & Jue, S. G. (1995). Assessment of sulfonylurea adherence and metabolic control. Diabetes Educator, 21, 52-57.
24. McNair, D., Lorr, M., & Droppleman, L. F. (1992). Manual for the profile of mood states (rev. ed.). San Diego, CA: EdITS/Educational and Industrial Testing Service.
25. Newman, L. A., & Singletary, S. E. (2007). Overview of adjuvant systemic therapy in early stage breast cancer. Surgical Clinics of North America, 87, 499-509. (Pubitemid 46711114)
26. Osterberg, L., & Blaschke, T. (2005). Adherence to medication. New England Journal of Medicine, 353, 487-497. (Pubitemid 41127293)
27. Partridge, A. H.,Wang, P. S.,Winer, E. P., &Avorn, J. (2003). Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. Journal of Clinical Oncology, 21, 602-606. (Pubitemid 46621892)
28. Rubin, R. R. (2005). Adherence to pharmacologic therapy in patients with type 2 diabetes mellitus. American Journal of Medicine, 118, 27SY34S. (Pubitemid 40585813)
29. Ruddy, K., Mayer, E., & Partridge, A. (2009). Patient adherence and persistence with oral anticancer treatment. CA: A Cancer Journal for Clinicians, 59, 56-66.
30. Sedjo, R. L., & Devine, D. (2011). Predictors of non-adherence to aromatase inhibitor therapy among commercially insured women with breast cancer. Breast Cancer Research and Treatment, 125, 191-200.
31. Spreen, O., & Strauss, E. (1998). A compendium of neuropsychological tests: Administration, norms, and commentary. New York, NY: Oxford University Press.
32. Sprinkle, S. D., Lurie, D., Insko, S. L, Atkinson, G., Jones, G. L., Logan, A. R.,&Bissada, N. N. (2002). Criterion validity, severity cut scores, and testYretest reliability of the Beck Depression Inventory-II in a university counseling center sample. Journal of Counseling Psychology, 49, 381-385.
33. Stanton, A. L., Bernaards, C. A., & Ganz, P. A. (2005). The BCPT Symptom Scales: A measure of physical symptoms for women diagnosed with or at risk for breast cancer. Journal of the National Cancer Institute, 97, 448-456. (Pubitemid 40528608)
34. Stukenberg, K. W., Dura, J. R., & Kiecolt-Glaser, J. K. (1990). Depression screening scale validation in an elderly, communitydwelling population. Psychological Assessment, 2, 134-138.
35. Terhorst, L., Blair-Belansky, H., Moore, P. J., & Bender, C. (2011). Evaluation of the psychometric properties of the BCPT Symptom Checklist with a sample of breast cancer patients before and after adjuvant therapy. Psycho-Oncology, 20, 961-968.
36. Wickersham, K., Happ, M. B., & Bender, C. M. (2012). "Keeping the boogie man away": Medication self-management among women receiving anastrozole therapy. Nursing Research and Practice, 462121.